Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:GBIO), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Fintel reports that on August 13, 2025, Wedbush downgraded their outlook for Generation Bio (NasdaqGS:GBIO) from Outperform to Neutral. Analyst Price Forecast Suggests 985.09% Upside As of August 6, ...

Wedbush analyst David Nierengarten on Wednesday downgraded Generation Bio (GBIO) to ‘Neutral’ from ‘Outperform’ with a $7 price target after the company announced a strategic restructuring. Shares of ...

• Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President For more information, please visit www.generationbio.com. Forward-Looking StatementsAny statements in this press release ...

Generation Bio is a biotechnology company aiming to treat autoimmune disorders by delivering gene-silencing molecules to T cells, a specific type of immune cell. Its platform centers on a proprietary ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...